---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-101272"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-09-15T23:59:59+00:00"
generated_at: "2026-06-10T15:53:48.315964+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eloxx Pharma R&D head Dr. Vijay Modur resigns effective Sept 30, 2023

## Summary
- Dr. Vijay Modur, Head of R&D, notified resignation effective September 30, 2023.
- No successor or interim appointment was disclosed in the filing.
- Resignation date of notification is September 15, 2023.

## SEC filing metadata
- accession: 0001104659-23-101272
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-09-15T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923101272/0001104659-23-101272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923101272/tm2326269d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-101272
- JSON: https://secwatch.observer/filing/0001104659-23-101272.json
- Plain text: https://secwatch.observer/filing/0001104659-23-101272.txt

## Key facts
- Executive change
  Dr. Vijay Modur resigned as Head of Research and Development at Eloxx Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Head of Research and Development
  source text: On September 15, 2023, Dr. Vijay Modur, Head of Research and Development of Eloxx Pharmaceuticals, Inc. (the “Company”), notified the Company of his resignation effective September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465923101272/0001104659-23-101272-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.